Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Trevi Therapeutics

NASDAQ TRVI
$2.77 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 17 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

275.66M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
243.57M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.02
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
99.52M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
106.72 %

Upcoming events Trevi Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Trevi Therapeutics

Stock analysis Trevi Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-8.21 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
3.34 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-6.39 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.84 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-46.40 7.67

Price change Trevi Therapeutics per year

1.18$ 3.98$
Min Max

Summary analysis Trevi Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Trevi Therapeutics

Revenue and net income Trevi Therapeutics

All parameters

Stock news Trevi Therapeutics

All news
19 September 2022 в 15:15

Trevi Therapeutics Reports Encouraging Results From Haduvio Trial

19 September 2022 в 15:10

Trevi Therapeutics Reports Encouraging Results From Haduvio Trial

29 June 2022 в 17:56

Trevi Therapeutics Shares Rise 19% After Positive Results for Haduvio Trial

29 June 2022 в 17:56

Trevi Therapeutics Shares Rise 19% After Positive Results for Haduvio Trial

25 May 2022 в 15:40

Trevi Therapeutics started at outperform with $10 stock price target at Oppenheimer

10 July 2020 в 16:10

Лидеры и аутсайдеры Уолл-cтрит: Hermitage Offshore Services, Matson, WiMi Hologram Cloud, Trevi Therapeutics

7 April 2020 в 15:28

Лидеры и аутсайдеры Уолл-стрит: Roadrunner Transportation, Trevi Therapeutics, Gannett Co

About company Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Address:
195 Church Street, New Haven, CT, United States, 06510
Company name: Trevi Therapeutics
Issuer ticker: TRVI
ISIN: US89532M1018
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2019-05-07
Sector: Healthcare
Industry: Biotechnology
Site: https://www.trevitherapeutics.com

On which stock exchange are Trevi Therapeutics (TRVI) stocks traded?

Trevi Therapeutics (TRVI) stocks are traded on NASDAQ.

What is the ticker of Trevi Therapeutics stocks (TRVI)?

The stock ticker of Trevi Therapeutics’s stocks or in other words, the code is TRVI. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Trevi Therapeutics (TRVI) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Trevi Therapeutics (TRVI) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Trevi Therapeutics (TRVI) stocks traded?

Trevi Therapeutics (TRVI) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Trevi Therapeutics (TRVI) stocks today?

The current price of Trevi Therapeutics stocks on 20.05.2024 is 2.77 dollars. per share.

What is the dynamics of Trevi Therapeutics (TRVI) stocks from the beginning of the year?

Trevi Therapeutics (TRVI) quotes have increased by 113.08% from the beginning of the year up to 2.77 dollars. per 1 stocks.

How much did Trevi Therapeutics (TRVI) stocks increase in мае 2024?

This month Trevi Therapeutics (TRVI) quotes have increased by -3.15% to 2.77 dollars. per share.

How much are Trevi Therapeutics (TRVI) stocks worth?

Today, on October, 20.05.2024 Trevi Therapeutics’s (TRVI) stocks cost 2.77 dollars..

What is the market capitalization of Trevi Therapeutics (TRVI)?

Capitalization is the market value of Trevi Therapeutics (TRVI) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of Trevi Therapeutics (TRVI) is estimated at about 275662677 dollars.